These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 22273086)

  • 41. Effect of treatment with natalizumab on ability to work in people with multiple sclerosis: productivity gain based on direct measurement of work capacity before and after 1 year of treatment.
    Olofsson S; Wickström A; Häger Glenngård A; Persson U; Svenningsson A
    BioDrugs; 2011 Oct; 25(5):299-306. PubMed ID: 21942914
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Swedish natalizumab (Tysabri) multiple sclerosis surveillance study.
    Piehl F; Holmén C; Hillert J; Olsson T
    Neurol Sci; 2011 Jan; 31 Suppl 3():289-93. PubMed ID: 20556456
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The Use of Natalizumab in Pediatric Patients With Active Relapsing Multiple Sclerosis: A Prospective Study.
    Alroughani R; Ahmed SF; Behbehani R; Al-Hashel J
    Pediatr Neurol; 2017 May; 70():56-60. PubMed ID: 28389054
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Safety and Effectiveness of Natalizumab: First Report of Interim Results of Post-Marketing Surveillance in Japan.
    Saida T; Yokoyama K; Sato R; Makioka H; Iizuka Y; Hase M; Ling Y; Torii S
    Neurol Ther; 2017 Dec; 6(2):197-211. PubMed ID: 29119538
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Natalizumab in the treatment of patients with multiple sclerosis: first experience.
    Mareckova H; Havrdova E; Krasulova E; Vankova Z; Koberová M; Sterzl I
    Ann N Y Acad Sci; 2007 Sep; 1110():465-73. PubMed ID: 17911462
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Validity and reliability of the Finnish version of the Multiple Sclerosis Impact Scale-29.
    Rosti-Otajärvi E; Hämäläinen P; Wiksten A; Hakkarainen T; Ruutiainen J
    Brain Behav; 2017 Jul; 7(7):e00725. PubMed ID: 28729932
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Health-related quality of life in multiple sclerosis: effects of natalizumab.
    Rudick RA; Miller D; Hass S; Hutchinson M; Calabresi PA; Confavreux C; Galetta SL; Giovannoni G; Havrdova E; Kappos L; Lublin FD; Miller DH; O'Connor PW; Phillips JT; Polman CH; Radue EW; Stuart WH; Wajgt A; Weinstock-Guttman B; Wynn DR; Lynn F; Panzara MA;
    Ann Neurol; 2007 Oct; 62(4):335-46. PubMed ID: 17696126
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Improvement of multiple sclerosis-associated tremor as a treatment effect of natalizumab.
    Rinker JR; Salter AR; Cutter GR
    Mult Scler Relat Disord; 2014 Jul; 3(4):505-12. PubMed ID: 25877063
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Effect of natalizumab on disease progression in secondary progressive multiple sclerosis (ASCEND): a phase 3, randomised, double-blind, placebo-controlled trial with an open-label extension.
    Kapoor R; Ho PR; Campbell N; Chang I; Deykin A; Forrestal F; Lucas N; Yu B; Arnold DL; Freedman MS; Goldman MD; Hartung HP; Havrdová EK; Jeffery D; Miller A; Sellebjerg F; Cadavid D; Mikol D; Steiner D;
    Lancet Neurol; 2018 May; 17(5):405-415. PubMed ID: 29545067
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Natalizumab induces a rapid improvement of disability status and ambulation after failure of previous therapy in relapsing-remitting multiple sclerosis.
    Belachew S; Phan-Ba R; Bartholomé E; Delvaux V; Hansen I; Calay P; Hafsi KE; Moonen G; Tshibanda L; Vokaer M
    Eur J Neurol; 2011 Feb; 18(2):240-245. PubMed ID: 20561044
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Natalizumab improves ambulation in relapsing-remitting multiple sclerosis: results from the prospective TIMER study and a retrospective analysis of AFFIRM.
    Voloshyna N; Havrdová E; Hutchinson M; Nehrych T; You X; Belachew S; Hotermans C; Paes D
    Eur J Neurol; 2015 Mar; 22(3):570-7. PubMed ID: 25511792
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Natalizumab therapy for highly active pediatric multiple sclerosis.
    Kornek B; Aboul-Enein F; Rostasy K; Milos RI; Steiner I; Penzien J; Hellwig K; Pitarokoili K; Storm van's Gravesande K; Karenfort M; Blaschek A; Meyer A; Seidl R; Debelic D; Vass K; Prayer D; Kristoferitsch W; Bayas A
    JAMA Neurol; 2013 Apr; 70(4):469-75. PubMed ID: 23420110
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Assessment of Clinically Meaningful Improvements in Self-Reported Walking Ability in Participants with Multiple Sclerosis: Results from the Randomized, Double-Blind, Phase III ENHANCE Trial of Prolonged-Release Fampridine.
    Hobart J; Ziemssen T; Feys P; Linnebank M; Goodman AD; Farrell R; Hupperts R; Blight AR; Englishby V; McNeill M; Chang I; Lima G; Elkins J;
    CNS Drugs; 2019 Jan; 33(1):61-79. PubMed ID: 30535670
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Natalizumab (Tysabri) prescription practices of neurologists in southern France].
    Rocher F; Cohen M; Lebrun C
    Rev Neurol (Paris); 2010 Apr; 166(4):412-8. PubMed ID: 19846185
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The value of anti-JCV antibody index assessment in multiple sclerosis patients treated with natalizumab with respect to demographic, clinical and radiological findings.
    Kolcava J; Hulova M; Benesova Y; Bednarik J; Stourac P
    Mult Scler Relat Disord; 2019 May; 30():187-191. PubMed ID: 30785075
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Assessment: the use of natalizumab (Tysabri) for the treatment of multiple sclerosis (an evidence-based review): report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology.
    Goodin DS; Cohen BA; O'Connor P; Kappos L; Stevens JC;
    Neurology; 2008 Sep; 71(10):766-73. PubMed ID: 18765653
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Quality of life among injectable and oral disease-modifying therapy users in the Pacific Northwest Multiple Sclerosis Registry.
    Stuchiner T; Lucas L; Baraban E; Spinelli KJ; Chen C; Smith A; Hashemi L; Cohan S
    BMC Neurol; 2020 Dec; 20(1):439. PubMed ID: 33272224
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Immune reconstitution inflammatory syndrome in natalizumab-associated PML.
    Tan IL; McArthur JC; Clifford DB; Major EO; Nath A
    Neurology; 2011 Sep; 77(11):1061-7. PubMed ID: 21832229
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Natalizumab Treatment for Relapsing-Remitting Multiple Sclerosis: The Experience From Saudi Arabia.
    Algahtani H; Shirah B; Abobaker H; Alghanaim N; Kamel F
    Clin Neuropharmacol; 2018; 41(6):199-201. PubMed ID: 30234558
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Safety and efficacy of natalizumab in Belgian multiple sclerosis patients: subgroup analysis of the natalizumab observational program.
    van Pesch V; Bartholomé E; Bissay V; Bouquiaux O; Bureau M; Caekebeke J; Debruyne J; Declercq I; Decoo D; Denayer P; De Smet E; D'hooghe M; Dubois B; Dupuis M; Sankari SE; Geens K; Guillaume D; van Landegem W; Lysandropoulos A; de Noordhout AM; Medaer R; Melin A; Peeters K; Ba RP; Retif C; Seeldrayers P; Symons A; Urbain E; Vanderdonckt P; Van Ingelghem E; Vanopdenbosch L; Vanroose E; Van Wijmeersch B; Willekens B; Willems C; Sindic C
    Acta Neurol Belg; 2014 Sep; 114(3):167-78. PubMed ID: 24915752
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.